WO2024254480A3 - Solid state forms of rencofilstat - Google Patents

Solid state forms of rencofilstat Download PDF

Info

Publication number
WO2024254480A3
WO2024254480A3 PCT/US2024/033050 US2024033050W WO2024254480A3 WO 2024254480 A3 WO2024254480 A3 WO 2024254480A3 US 2024033050 W US2024033050 W US 2024033050W WO 2024254480 A3 WO2024254480 A3 WO 2024254480A3
Authority
WO
WIPO (PCT)
Prior art keywords
rencofilstat
solid state
state forms
same
forms
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2024/033050
Other languages
French (fr)
Other versions
WO2024254480A2 (en
Inventor
Robert Thomas FOSTER
Daniel Joseph TREPANIER
Thomas Paul ZABAWA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hepion Pharmaceuticals Inc
Original Assignee
Hepion Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hepion Pharmaceuticals Inc filed Critical Hepion Pharmaceuticals Inc
Priority to EP24820149.3A priority Critical patent/EP4724081A2/en
Priority to AU2024285817A priority patent/AU2024285817A1/en
Publication of WO2024254480A2 publication Critical patent/WO2024254480A2/en
Publication of WO2024254480A3 publication Critical patent/WO2024254480A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • C07K7/645—Cyclosporins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

This invention relates to solid state forms of Rencofilstat (RCF), pharmaceutical compositions comprising the same, and methods of manufacturing pharmaceutical dosage forms utilizing the same.
PCT/US2024/033050 2023-06-08 2024-06-07 Solid state forms of rencofilstat Ceased WO2024254480A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP24820149.3A EP4724081A2 (en) 2023-06-08 2024-06-07 Solid state forms of rencofilstat
AU2024285817A AU2024285817A1 (en) 2023-06-08 2024-06-07 Solid state forms of rencofilstat

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363471879P 2023-06-08 2023-06-08
US63/471,879 2023-06-08

Publications (2)

Publication Number Publication Date
WO2024254480A2 WO2024254480A2 (en) 2024-12-12
WO2024254480A3 true WO2024254480A3 (en) 2025-01-16

Family

ID=93794711

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2024/033050 Ceased WO2024254480A2 (en) 2023-06-08 2024-06-07 Solid state forms of rencofilstat

Country Status (3)

Country Link
EP (1) EP4724081A2 (en)
AU (1) AU2024285817A1 (en)
WO (1) WO2024254480A2 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150065433A1 (en) * 2010-10-12 2015-03-05 Allergan, Inc. Cyclosporin analogs
US20160207961A1 (en) * 2010-12-15 2016-07-21 Ciclofilin Pharmaceuticals Corp. Cyclosporine Analogue Molecules Modified At Amino Acid 1 and 3
US20220168385A1 (en) * 2020-11-29 2022-06-02 Hepion Pharmaceuticals, Inc. Use of cyclosporine analogues as antithrombotic agents

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150065433A1 (en) * 2010-10-12 2015-03-05 Allergan, Inc. Cyclosporin analogs
US20160207961A1 (en) * 2010-12-15 2016-07-21 Ciclofilin Pharmaceuticals Corp. Cyclosporine Analogue Molecules Modified At Amino Acid 1 and 3
US20220168385A1 (en) * 2020-11-29 2022-06-02 Hepion Pharmaceuticals, Inc. Use of cyclosporine analogues as antithrombotic agents

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
HARRISON STEPHEN A., MAYO PATRICK R., HOBBS TODD M., CANIZARES CARLOS, FOSTER ERIN P., ZHAO CAROLINE, URE DAREN R., TREPANIER DANI: "Rencofilstat, a cyclophilin inhibitor: A phase 2a, multicenter, single‐blind, placebo‐controlled study in F2/F3 NASH", HEPATOLOGY COMMUNICATIONS, vol. 6, no. 12, 1 December 2022 (2022-12-01), pages 3379 - 3392, XP093266737, ISSN: 2471-254X, DOI: 10.1002/hep4.2100 *

Also Published As

Publication number Publication date
AU2024285817A1 (en) 2026-01-08
WO2024254480A2 (en) 2024-12-12
EP4724081A2 (en) 2026-04-15

Similar Documents

Publication Publication Date Title
EP4512399A3 (en) Solid state forms of tafamidis and salts thereof
WO2020083971A3 (en) New anthelmintic compounds
EP4360651A3 (en) Glp-1 compositions and uses thereof
EP4674481A3 (en) Cd73 inhibitors
AR033711A1 (en) PHARMACEUTICAL COMPOSITIONS
EP4400098A3 (en) Co-amorphous forms of beta-lactoglobulin and a drug substance
MXPA03011546A (en) New use.
WO2022106902A8 (en) Benzenesulfonamide derivatives and uses thereof
HK1041816A1 (en) Pharmaceutical tablets
AU2022215028A9 (en) Solid pharmaceutical compositions and methods of producing the same
WO2005097076A3 (en) Low dose pharmaceutical products
WO2002094856A3 (en) Gpe analogs and peptidomimetics
WO2022207944A3 (en) Mixtures and uses of (2e)-3-(1,3-benzodioxol-5-yl)-n-phenyl-n-(tetrahydro-3-furanyl)-2-propenamide
WO2024023585A3 (en) Urolithin and fluorene derivatives for inhibiting ferroptosis
WO2025057086A3 (en) Pharmaceutical compositions comprising nipocalimab
WO2024163530A3 (en) Novel anti-ccr4 antibodies and derivative products
WO2007087026A3 (en) Solid-state form of amg 706 and pharmaceutical compositions thereof
WO2024015559A3 (en) Solid forms of mesembrine and therapeutic uses thereof
WO2025094081A3 (en) Solid state forms of deutivacaftor
WO2023168249A3 (en) Cysteamides, therapeutic compositions thereof, and related methods
WO2022040111A3 (en) Solid state forms of erdafitinib salts and processes for preparation of erdafitinib
WO2020086650A3 (en) Novel compounds
WO2024173800A3 (en) Solid forms of mesembranol and therapeutic uses thereof
WO2026027799A3 (en) Amorphous solid form and pharmaceutical compositions of lenvatinib besylate
WO2023205783A3 (en) Oral cannabinoid pharmaceutical compositions and methods of treating inflammatory gastrointestinal disorders

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: AU2024285817

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2025571429

Country of ref document: JP

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2024285817

Country of ref document: AU

Date of ref document: 20240607

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2024820149

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2024820149

Country of ref document: EP

Effective date: 20260108

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 24820149

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2024820149

Country of ref document: EP

Effective date: 20260108

ENP Entry into the national phase

Ref document number: 2024820149

Country of ref document: EP

Effective date: 20260108

ENP Entry into the national phase

Ref document number: 2024820149

Country of ref document: EP

Effective date: 20260108

ENP Entry into the national phase

Ref document number: 2024820149

Country of ref document: EP

Effective date: 20260108

WWP Wipo information: published in national office

Ref document number: 2024820149

Country of ref document: EP